-
公开(公告)号：US20180171018A1
公开(公告)日：2018-06-21
申请号：US15878344
申请日：2018-01-23
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien KUO , Javier Fernando CHAPARRO RIGGERS , Wei CHEN , Amy Shaw-Ru CHEN , Edward Derrick PASCUA , Thomas John VAN BLARCOM , Leila Marie BOUSTANY , Weihsien HO , Yik Andy YEUNG , Pavel STROP , Arvind RAJPAL
IPC: C07K16/28 , A61K39/395 , A61K47/68 , A61K31/454 , A61K31/69 , A61K31/704 , A61K39/00
CPC classification number: C07K16/2878 , A61K31/454 , A61K31/69 , A61K31/704 , A61K39/3955 , A61K39/39558 , A61K47/6801 , A61K47/6849 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , A61K2300/00
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
-
公开(公告)号：US20210054087A1
公开(公告)日：2021-02-25
申请号：US17005073
申请日：2020-08-27
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien KUO , Javier Fernando CHAPARRO RIGGERS , Wei CHEN , Amy Shaw-Ru CHEN , Edward Derrick PASCUA , Thomas John VAN BLARCOM , Leila Marie BOUSTANY , Weihsien HO , Yik Andy YEUNG , Pavel STROP , Arvind RAJPAL
IPC: C07K16/28 , A61K39/395 , A61K31/454 , A61K31/704 , A61K31/69 , A61K47/68
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
-
公开(公告)号：US20160297885A1
公开(公告)日：2016-10-13
申请号：US15085644
申请日：2016-03-30
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien KUO , Javier Fernando CHAPARRO RIGGERS , Wei CHEN , Amy Shaw-Ru CHEN , Edward Derrick PASCUA , Thomas John VAN BLARCOM , Leila Marie BOUSTANY , Weihsien HO , Yik Andy YEUNG , Pavel STROP , Arvind RAJPAL
IPC: C07K16/28 , A61K31/704 , A61K38/07 , A61K38/05 , A61K39/395 , A61K31/454
CPC classification number: C07K16/2878 , A61K31/454 , A61K31/69 , A61K31/704 , A61K39/3955 , A61K39/39558 , A61K47/6801 , A61K47/6849 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , A61K2300/00
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
Abstract translation: 本发明涉及特异性结合BCMA（B细胞成熟抗原）和/或CD3（分化群3）的抗体，例如全长抗体或其抗原结合片段。 本发明还涉及包含BCMA抗体的抗体缀合物（例如，抗体 - 药物偶联物），包含BCMA抗体的组合物，以及使用BCMA抗体及其缀合物治疗与表达BCMA的细胞相关的病症的方法（例如癌症或 自身免疫性疾病）。 本发明还涉及特异性结合CD3和肿瘤细胞抗原的异源多聚体抗体（例如，特异性结合CD3和BCMA的双特异性抗体）。 还提供了包含这种异源多聚体抗体的组合物，用于产生和纯化此类异二聚体抗体的方法及其在诊断和治疗中的应用。
-
公开(公告)号：US20240018252A1
公开(公告)日：2024-01-18
申请号：US18456399
申请日：2023-08-25
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien KUO , Javier Fernando CHAPARRO RIGGERS , Wei CHEN , Amy Shaw-Ru CHEN , Edward Derrick PASCUA , Thomas John VAN BLARCOM , Leila Marie BOUSTANY , Weihsien HO , Yik Andy YEUNG , Pavel STROP , Arvind RAJPAL
IPC: C07K16/28 , A61K31/454 , A61K39/395 , A61K38/07 , A61P35/00 , A61K31/704
CPC classification number: C07K16/2878 , C07K16/2809 , A61K31/454 , A61K39/3955 , A61K38/07 , A61P35/00 , A61K31/704 , C07K2317/31 , A61K39/00
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
-
公开(公告)号：US20230192839A1
公开(公告)日：2023-06-22
申请号：US16500970
申请日：2018-03-29
Applicant: PFIZER INC.
Inventor： Bijan Andre BOLDAJIPOUR , Javier Fernando CHAPARRO RIGGERS , Xiaodi DENG , Kevin Charles LINDQUIST , Spencer PARK , Edward Derrick PASCUA , Thomas John VAN BLARCOM
CPC classification number: C07K16/28 , C07K16/005 , C12N15/63 , C07K2317/92 , C07K2317/565 , C07K2317/622 , C07K2319/03
Abstract: Provided herein are antibodies with conditional affinity for an antigen. The affinity of an antibody with conditional affinity for an antigen may be altered by a small molecule agent. Antibodies with conditional affinity may be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
-
Patent Agency Ranking
公开(公告)号：US20200024366A1
公开(公告)日：2020-01-23
申请号：US16296852
申请日：2019-03-08
Applicant: Pfizer Inc. , RINAT NEUROSCIENCE CORP.
Inventor： Jaume PONS , Jeffrey Raymond CHABOT , Javier Fernando CHAPARRO RIGGERS , Bruce Charles GOMES , Hong LIANG , KapiI MAYAWALA , Jerome Thomas METTETAL, II , Arvind RAJPAL , David Louis SHELTON
Abstract: The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the KD or koff ratio at pH 5.5/pH 7.4 or at pH 6.0/pH 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. Such pH dependent antibodies preferentially dissociate from the antigen in the endosome. This can increase antibody half life, as compared to antibodies with equivalent KDs at pH 7.4 but with no pH dependent binding, when the antigen is one that undergoes antigen-mediated clearance (e.g., PCSK9). Antibodies with pH dependent binding can decrease total antigen half life when the antigen undergoes reduced clearance when bound to antibody (e.g., IL6). Antibodies with pH dependent binding can also prolong the decrease in antigen which is not antibody-bound. This can be important when antagonizing a target antigen typically present at high levels (e.g., IgE, DKK1, C5 and SOST). In addition, such antibodies can increase antigen half life when the antigen is a receptor and the receptor has increased clearance when bound to antibody (e.g., GMCSF receptor).
-
公开(公告)号：US20180298108A1
公开(公告)日：2018-10-18
申请号：US16017974
申请日：2018-06-25
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien KUO , Javier Fernando CHAPARRO RIGGERS , Wei CHEN , Amy Shaw-Ru CHEN , Edward Derrick PASCUA , Thomas John VAN BLARCOM , Leila Marie BOUSTANY , Weihsien HO , Yik Andy YEUNG , Pavel STROP , Arvind RAJPAL
IPC: C07K16/28 , A61K39/395 , A61K31/704 , A61K31/454 , A61K47/68
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
-
公开(公告)号：US20240010696A1
公开(公告)日：2024-01-11
申请号：US18335259
申请日：2023-06-15
Applicant: Pfizer Inc.
Inventor： James Reasoner APGAR , Javier Fernando CHAPARRO RIGGERS , Ling Hon Matthew CHU , Tzu-Hsuan HUANG , Kritika MOHAN , Lidia MOSYAK , Edward Derrick PASCUA , James Travis PATTERSON , Gabriel Roy STARBECK-MILLER , Dirk Michael ZAJONC
CPC classification number: C07K14/5434 , C07K16/2818 , A61P35/00 , C12N15/63 , C07K2317/565
Abstract: IL-12 variants are provided. Also provided are antibodies that specifically bind to PD1. Also provided are fusion proteins of IL-12 variants and anti-PD1 antibodies. Also provided are uses of these IL-12 variants, anti-PD1 antibodies, fusion proteins, and related compositions and methods.
-
公开(公告)号：US20230365701A1
公开(公告)日：2023-11-16
申请号：US18315054
申请日：2023-05-10
Applicant: Pfizer Inc.
Inventor： James Reasoner APGAR , Bas Joannes Gertrudis BAATEN , Aruna BITRA , Javier Fernando CHAPARRO RIGGERS , Giuseppe DI CARO , Pawel Kamil DOMINIK , Zachary John MABEN , Lidia MOSYAK , Andrew Ross NAGER , Cecilia Marianne ODERUP , Edward Derrick PASCUA , Shahram SALEK-ARDAKANI , Dirk Michael ZAJONC
CPC classification number: C07K16/2878 , A61P35/00 , C07K2317/35 , C07K2317/71 , C07K2317/92 , A61K2039/505
Abstract: Antibodies that specifically bind to LTBR are provided. Also provided are uses of these antibodies, and related compositions and methods.
-
公开(公告)号：US20190241669A1
公开(公告)日：2019-08-08
申请号：US16384719
申请日：2019-04-15
Applicant: Pfizer Inc.
Inventor： Tracy Chia-Chien KUO , Bijan Andre BOLDAJIPOUR , Javier Fernando CHAPARRO RIGGERS , Philippe DUCHATEAU , Roman Ariel GALETTO , Alexandre JUILLERAT , Thomas Charles PERTEL , Arvind RAJPAL , Barbra Johnson SASU , Cesar Adolfo SOMMER , Julien VALTON , Thomas John VAN BLARCOM
IPC: C07K16/28 , C07K14/705 , A61K31/7076 , A61K35/17 , C12N15/63 , C07K14/725 , A61K39/00
CPC classification number: C07K16/2878 , A61K31/7076 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/505 , A61K2039/5156 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K16/2863 , C07K16/2896 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C12N15/63
Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.017 seconds)
